149 related articles for article (PubMed ID: 7787692)
1. [A mathematical analysis of the cardiac activity indices in patients with ischemic heart disease undergoing antianginal pharmacotherapy].
Arushanian EB; Shamliian TA
Eksp Klin Farmakol; 1995; 58(1):31-3. PubMed ID: 7787692
[TBL] [Abstract][Full Text] [Related]
2. [The chronobiological aspects of drug resistance to antianginal therapy].
Arushanian EB; Shamliian TA
Eksp Klin Farmakol; 1994; 57(4):33-5. PubMed ID: 7950781
[TBL] [Abstract][Full Text] [Related]
3. [The effect of antianginal preparations on the hemodynamics and metabolism of the ischemic myocardium].
Makolkin VI; Vakhliaev VD
Eksp Klin Farmakol; 1996; 59(4):18-20. PubMed ID: 9026181
[TBL] [Abstract][Full Text] [Related]
4. [The use of the new cardioprotective agent thiotriazoline in the therapy of ischemic heart disease in older patients].
Dunaev VV; Kraĭdashenko OV; Berezin AE
Eksp Klin Farmakol; 1996; 59(1):21-3. PubMed ID: 8704625
[TBL] [Abstract][Full Text] [Related]
5. [The detection of circadian fluctuations in the efficacy of pharmacotherapy in patients with ischemic heart disease using cardiointervalography].
Arushanian EB; Shamliian TA
Eksp Klin Farmakol; 1996; 59(2):24-6. PubMed ID: 8974558
[TBL] [Abstract][Full Text] [Related]
6. [Fluctuations in the stenocardia threshold of patients with ischemic heart disease].
Kuleshova EV; Gusarov GV; Tsaĭ NV
Ter Arkh; 1992; 64(4):23-6. PubMed ID: 1440301
[TBL] [Abstract][Full Text] [Related]
7. [The use of the antioxidant coenzyme Q10 as a cytoprotection variant in ischemic heart disease].
Syrkin AL; Kogan AKh; Drinitsina SV; Kuznetsov AB; Pechorina EA; Frenkel' EE; Kuleshova NN; Golovnia LD
Klin Med (Mosk); 1998; 76(7):24-8. PubMed ID: 9742773
[No Abstract] [Full Text] [Related]
8. [Psychophysiological approaches to assessing patients with painful and painless forms of ischemic heart disease].
Lipovetskii BM; Reznikova TN; Il'ina GN; Petukhova NV; Stoianov AM
Ter Arkh; 1995; 67(12):8-11. PubMed ID: 8820044
[TBL] [Abstract][Full Text] [Related]
9. [Effect of a compound preparation pumpan on exercise tolerance and clinical course of ischemic heart disease].
Krasnitskiĭ VB; Aronov DM; Zhidko NI
Ter Arkh; 2003; 75(8):17-21. PubMed ID: 14520844
[TBL] [Abstract][Full Text] [Related]
10. [Increased myocardial resistance to ischemia in a chronic model of stenocardia].
Pozin VM; Skuratovskaia SG; Pocheptsova GA
Biull Eksp Biol Med; 1993 Sep; 116(9):235-8. PubMed ID: 7509646
[No Abstract] [Full Text] [Related]
11. [A clinico-pharmacological study of the antianginal and anti-ischemic efficacy of a new drug form of diltiazem with delayed release].
Belousov IuB; Upnitskiĭ AA; Sokolov AV; Tishchenkova NF; Karasev AV; Egorova NA
Ter Arkh; 1997; 69(3):61-3. PubMed ID: 9229836
[No Abstract] [Full Text] [Related]
12. [Consequences of circadian variability for the treatment of ischemic heart disease].
Herren T; Urban P; Rutishauser W
Schweiz Rundsch Med Prax; 1992 Feb; 81(7):176-82. PubMed ID: 1535952
[TBL] [Abstract][Full Text] [Related]
13. [The tourniquet test in evaluating the analgesic action of antianginal preparations].
Zhiliaev EV; Glazunov AV
Ter Arkh; 1993; 65(4):40-3. PubMed ID: 8059406
[TBL] [Abstract][Full Text] [Related]
14. Circadian variation of ischaemic events in patients with chronic stable angina: pathophysiological and therapeutical considerations.
Chierchia SL
Arch Mal Coeur Vaiss; 1993 Jun; 86 Spec No 3():11-4. PubMed ID: 7904444
[TBL] [Abstract][Full Text] [Related]
15. [The effect of helium-neon laser irradiation on myocardial and thyroid functions in patients with ischemic heart disease].
Ruzov VI; Rubanova MP; Grigor'ev MIu; Cherkunov KV
Vopr Kurortol Fizioter Lech Fiz Kult; 1997; (5):7-9. PubMed ID: 9446315
[No Abstract] [Full Text] [Related]
16. [The possibilities for the pathogenetic therapy of ischemic heart disease under cardioselective loading].
Ardashev VN; Smirnov AV; Ryndin AA; Shcherbak IuA
Voen Med Zh; 1994 Jul; (7):29-31, 79. PubMed ID: 7810109
[TBL] [Abstract][Full Text] [Related]
17. [An amino acid metabolic complex in optimizing the cardiac hemodynamic characteristics of patients with ischemic heart disease].
Berezin AE; Fushteĭ IM; Kraĭdashenko OV
Lik Sprava; 1998 Dec; (8):94-6. PubMed ID: 10204359
[TBL] [Abstract][Full Text] [Related]
18. [How efficacy of antianginal drugs should be evaluated].
Kośmicki M; Kowalik I; Sadowski Z
Przegl Lek; 2000; 57(7-8):411-4. PubMed ID: 11109316
[TBL] [Abstract][Full Text] [Related]
19. [The optimization of the hemodynamic characteristics in patients with ischemic heart disease and circulatory failure by using a substrate-coenzyme complex].
Vizir AD; Dunaev VV; Berezin AE; Kraĭdashenko OV
Lik Sprava; 1997; (5):53-6. PubMed ID: 9491697
[TBL] [Abstract][Full Text] [Related]
20. [Agents for the metabolic correction of myocardial energy metabolism in treating patients with ischemic heart disease].
Vizyr AD; Kraĭdashenko OV; Berezin OIe; Oliĭnyk OI
Lik Sprava; 2000 Mar; (2):26-30. PubMed ID: 10862469
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
